Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Debio 0123 + RP-6306 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Debio 0123 | Debio-0123|Debio0123 | WEE1 Inhibitor 8 | Debio 0123 is an ATP-competitive inhibitor of Wee1 that suppresses CDK1 phosphorylation, which may lead to tumor growth inhibition (Cancer Res 2019;79(13 Suppl):Abstract nr 4423). | |
| RP-6306 | RP6306|RP 6306|Lunresertib | PKMYT1 Inhibitor 4 | RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest, apoptosis, and decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT262, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04855656 | Phase I | RP-6306 Debio 0123 + RP-6306 RP-3500 + RP-6306 | Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC) | Recruiting | USA | GBR | DNK | CAN | 0 |